Clinical analysis of acute myeloid leukemia with t(8;21) (q22;q22) and loss of Y chromosome.
10.7534/j.issn.1009-2137.2014.04.013
- Author:
Cheng-Ying ZHU
1
;
Hua YANG
1
;
Jian-Hua NIU
2
;
Qi ZHANG
3
;
Xu-Lei XIE
4
;
Li-Jun WANG
5
;
Hai-Yan ZHU
1
;
Zi-Long YAO
1
;
Li YU
1
;
Yu JING
6
Author Information
1. Department of Hematology, Chinese PLA General Hospital Beijing 1000853.
2. Department of Hematology, The Forth People's Hospital of Jinan, Jinan 250031, Shandong Province, China.
3. Department of Hematology, People's Hospital of Gaochun, Nanjing 211300, Jiangsu Province, China.
4. Department of Hematology, The First People's Hospital of Baoding, Baoding 071000, Hebei Province, China.
5. Department of Hematology, Chinese PLA 264 Hospital, Taiyuan 030001, Shaixi Province, China.
6. Department of Hematology, Chinese PLA General Hospital Beijing 1000853. E-mail :jingyu301@126.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Chromosome Deletion;
Chromosomes, Human, Pair 21;
Chromosomes, Human, Pair 8;
Chromosomes, Human, Y;
Female;
Humans;
Leukemia, Myeloid, Acute;
genetics;
therapy;
Male;
Middle Aged;
Recurrence;
Remission Induction;
Retrospective Studies;
Translocation, Genetic;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(4):950-956
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical characteristics of acute myeloid leukemia (AML) with t (8;21) (q22;q22) and loss of Y chromosomes. Clinical data of 267 cases of AML were collected from January 2010 to June 2013. Among 267 AML, there were 13 cases with t (8;21) (q22;q22) and loss of Y chromosomes. The clinical data including clinical indicators, treatment protocols, curative effect and prognosis were analyzed retrospectively. The results showed that after normalized chemotherapy, there were 4 patients with complete remission at the first cycle of treatment, 4 patients with complete remission at the second cycle, 4 patients with complete remission at the third cycle, but one patient without complete remission after 4 cycles. There were 6 patients who did not relapse during consolidation and intensive therapy. Among these 6 patients, 4 cases accepted chemotherapy combined with transplantation, other 2 cases accepted chemotherapy. In the remainder 6 patients, 4 cases relapsed once, one cases relapsed twice, 1 cases relapsed for three times. Moreover, 2 cases who accepted the chemotherapy and auto-hematopoietic stem cell trans-plantation, were diagnosed as relapse, after accepted allo-hematopoietic stem cell transplantation, currently are in disease-free status. In follow-up period, the relapse-free survival (RFS) time was 4.67 ± 3.45 months in chemotherapy group, the RFS time is 34.17 ± 21.37 months in chemotherapy and transplantation group. The chemotherapy combined with transplantation extended the RFS time (P < 0.05). It is concluded that the NCCN guide indicates that AML with t (8;21) ( q22;q22) showed a good prognosis. but the clinical course of treatment confirmed that the prognosis of AML patients with t (8;21) (q22;q22) and loss Y chromosomes is poor, including uneasy remission and easy relapse, for improving the prognosis of these patients, the hematopoietic stem cell transplantation should be recommended.
